Information Provided By: 
Fly News Breaks for October 21, 2015
PTCT
Oct 21, 2015 | 08:06 EDT
JPMorgan analyst Anupam Rama there is enough within the efficacy data to support a potential approval of PTC Therapeutics' Translarna in Duchene Muscular Dystrophy. Rama does not see risk of the drug being pulled from European market given its "very clear safety profile." The analyst cut his price target for PTC shares to $81 from $84 and reiterates an Overweight rating on the name.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
